Please login to the form below

Not currently logged in
Email:
Password:

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

The investigational CAR-Ts have shown promising early-stage results in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL), the companies said, with the majority of patients in the studies ... forward to harnessing our expertise,

Latest news

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • CAR-T cell therapy in oncology CAR-T cell therapy in oncology

    While ‘traditional’ therapeutics are produced in large batches for many people at once, CAR-Ts are typically manufactured in smaller – sometimes single dose – batches. ... Until recently, CAR-Ts were autologous therapies where the raw biological

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are

  • Deal Watch October 2018

    FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    therapies, such as CAR-Ts Kymriah and Yescarta.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space

    As more CAR-Ts have obtained marketing authorisation in the intervening years, similar questions have also been on the minds of payers and policymakers making decisions about how – and in which ... In this article for pharmaphorum's Oncology Deep Dive,

  • White paper: Are we prepared for the influx of CAR-Ts?

    Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer

  • Understanding the evolving CAR-T market

    In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... More than 500 CAR-Ts are in development, making competition fierce. Earlier this year

  • Blue Latitude Health Blue Latitude Health

    In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy

  • Research Partnership Research Partnership

    Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space. ... White paper: Are we prepared for the influx of CAR-Ts?.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....